Compass Pathways PLC
NASDAQ:CMPS
Compass Pathways PLC
Total Equity
Compass Pathways PLC
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Total Equity
$154.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
79%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Total Equity
$401.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Equity
£381m
|
CAGR 3-Years
11%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Equity
£504m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Equity
£32.7m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
7%
|
|
|
Niox Group PLC
LSE:NIOX
|
Total Equity
£64.4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-17%
|
|
Compass Pathways PLC
Glance View
Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is focused on treatment-resistant depression (TRD). The company is developing COMP360, a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. Psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360 administration.
See Also
What is Compass Pathways PLC's Total Equity?
Total Equity
154.7m
USD
Based on the financial report for Dec 31, 2024, Compass Pathways PLC's Total Equity amounts to 154.7m USD.
What is Compass Pathways PLC's Total Equity growth rate?
Total Equity CAGR 5Y
79%
Over the last year, the Total Equity growth was -31%. The average annual Total Equity growth rates for Compass Pathways PLC have been -18% over the past three years , 79% over the past five years .
